期刊
NEUROPSYCHOPHARMACOLOGY
卷 34, 期 10, 页码 2305-2322出版社
SPRINGERNATURE
DOI: 10.1038/npp.2009.58
关键词
glutamate; dopamine; antipsychotic; GLS1; mouse; imaging
资金
- NIMH [P50 MH066171, R01 MH068073]
- NIDA [K02 DA000356, T32 DA016224, R01 DA016373]
- NIA [R01 AG025161]
- NINDS [R01 NS049442]
- Joe Young Sr. Research Fund in Psychiatry (MPG)
- Wayne State Anesthesiology Research Fund (MPG)
- Rothschild Foundation (IGS)
Dysregulated glutamatergic neurotransmission has been strongly implicated in the pathophysiology of schizophrenia (SCZ). Recently, presynaptic modulation of glutamate transmission has been shown to have therapeutic promise. We asked whether genetic knockdown of glutaminase (gene GLS1) to reduce glutamatergic transmission presynaptically by slowing the recycling of glutamine to glutamate, would produce a phenotype relevant to SCZ and its treatment. GLS1 heterozygous (GLS1 het) mice showed about a 50% global reduction in glutaminase activity, and a modest reduction in glutamate levels in brain regions relevant to SCZ pathophysiology, but displayed neither general behavioral abnormalities nor SCZ-associated phenotypes. Functional imaging, measuring regional cerebral blood volume, showed hippocampal hypometabolism mainly in the CA1 subregion and subiculum, the inverse of recent clinical imaging findings in prodromal and SCZ patients. GLS1 het mice were less sensitive to the behavioral stimulating effects of amphetamine, showed a reduction in amphetamine-induced striatal dopamine release and in ketamine-induced frontal cortical activation, suggesting that GLS1 het mice are resistant to the effects of these pro-psychotic challenges. Moreover, GLS1 het mice showed clozapine-like potentiation of latent inhibition, suggesting that reduction in glutaminase has antipsychotic-like properties. These observations provide further support for the pivotal role of altered glutamatergic synaptic transmission in the pathophysiology of SCZ, and suggest that presynaptic modulation of the glutamine-glutamate pathway through glutaminase inhibition may provide a new direction for the pharmacotherapy of SCZ. Neuropsychopharmacology (2009) 34, 2305-2322; doi: 10.1038/npp.2009.58; published online 10 June 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据